Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Faeth Therapeutics, Inc./ 10-Q

Quarterly Report · 10-Q

Faeth Therapeutics, Inc.

FTHNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 4, 2026Accepted Aug 4, 2026, 7:40 AM EDTCIK 1829802Accession 0001193125-26-331562
View company →Permanent SEC source ↗
Share

Company context

Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph. D., together with scientific founders Lewis Cantley, Ph. D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph. D.; Scott Lowe, Ph. D.; and Greg Hannon, Ph. D. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.

Current securities

FTHNASDAQ · EQUITY · Current

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 27, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 17, 2026
  3. 4 filingSep 15, 2026
  4. 3 filingSep 15, 2026
  5. SCHEDULE 13G/A - filed by Caligan Partners LP regarding Faeth Therapeutics, Inc.Aug 14, 2026

Registered securities in this filing

Faeth Therapeutics, Inc. · 10-Q · Filed 2026-08-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value per share

Symbol
FTH
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_2fb4def6-fdef-4b22-8405-8baf4eb2e015

Dimensions: Not supplied

Accession 000119312526331562 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.